2002
DOI: 10.1046/j.1537-2995.2002.00022.x
|View full text |Cite
|
Sign up to set email alerts
|

Effectiveness of WBC reduction in neonates: what is the evidence of benefit?

Abstract: Current evidence suggests that WBC reduction may be effective in neonates; however, further studies are needed. The lack of convincing data and the significant cost of WBC reduction mandate evaluations to determine the clinical and economic impact.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

0
15
0

Year Published

2003
2003
2019
2019

Publication Types

Select...
5
3

Relationship

1
7

Authors

Journals

citations
Cited by 21 publications
(15 citation statements)
references
References 31 publications
0
15
0
Order By: Relevance
“…The United States and Japan do not practice universal leukoreduction. 21, 22 The evidence to support leukoreduction is mixed and suggests that leukoreduction has no effect on clinical outcomes in certain patient populations, including trauma patients. 2225 Furthermore, leukoreduction is expensive.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…The United States and Japan do not practice universal leukoreduction. 21, 22 The evidence to support leukoreduction is mixed and suggests that leukoreduction has no effect on clinical outcomes in certain patient populations, including trauma patients. 2225 Furthermore, leukoreduction is expensive.…”
Section: Discussionmentioning
confidence: 99%
“…21, 22 The evidence to support leukoreduction is mixed and suggests that leukoreduction has no effect on clinical outcomes in certain patient populations, including trauma patients. 2225 Furthermore, leukoreduction is expensive. 26 Because of conflicting data supporting its efficacy concerning patient outcomes and significant difference in cost, further studies are required before leukoreduction will be required worldwide.…”
Section: Discussionmentioning
confidence: 99%
“…Sepsis in the ET group may also have been caused by administration of infected blood products. Although the current risk of transmission of infectious diseases is relatively low, it is not completely negligible [5,21]. Furthermore, ET-related washout of leukocytes may also play a role in the higher incidence of sepsis in the ET group, since in double-volume ET, more than 90% of circulating blood is replaced by leukocyte-depleted donor blood [21,22].…”
Section: Discussionmentioning
confidence: 99%
“…Although the current risk of transmission of infectious diseases is relatively low, it is not completely negligible [5,21]. Furthermore, ET-related washout of leukocytes may also play a role in the higher incidence of sepsis in the ET group, since in double-volume ET, more than 90% of circulating blood is replaced by leukocyte-depleted donor blood [21,22]. Finally, limited data on leukocytopenia in neonates with HDFN due to red cell alloimmunization show that the risk of leukocytopenia is increased in severe Rhesus HDFN [23,24].…”
Section: Discussionmentioning
confidence: 99%
“…There is debate about the data of Ohto et al, 23 suggesting that gamma irradiation of blood can reduce the chance of post-transfusion CMV infection by interfering with the allograft reaction ability of the donor lymphocytes needed to activate latent CMV in leukocytes. 24,25 Blood transfused to our infants has been gamma irradiated, possibly reducing this mode of acquisition of CMV.…”
Section: Discussionmentioning
confidence: 99%